Key result
Amiodarone use in ARVC patients with ICDs was associated with a lower risk of clinically relevant ventricular arrhythmias.
Why the study?
No studies have provided data on the efficacy of antiarrhythmic drugs in a rigorously screened cohort of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC).
Do empiric antiarrhythmic drugs reduce the risk of ventricular arrhythmias in patients with ARVC and ICDs?
Cohort (n=95)
Yes
Do empiric antiarrhythmic drugs reduce the risk of ventricular arrhythmias in patients with ARVC and ICDs?
Answers are grounded in this paper and cite their sources.
In patients with ARVC and ICDs, amiodarone appears superior to beta-blockers and sotalol in preventing ventricular arrhythmias, though data is limited by small sample size.
Antiarrhythmic drugs are important in protecting against ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy (ARVC), but no studies have provided data in a group rigorously screened for the disease. To examine the efficacy of empiric antiarrhythmic drugs in a rigorously characterized cohort of ARVC patients. Antiarrhythmic medicines were examined in all subjects with implantable cardioverter-defibrillators (ICDs) enrolled in the North American ARVC/D Registry. A Cox proportional hazards model was used to account for time on each drug, and a hierarchical analysis was performed for repeated measures within individuals. Ninety-five patients were studied, with a mean follow-up of 480 ± 389 days. Fifty-eight (61%) received beta-blockers, and these medicines were not associated with an increased or decreased risk of ventricular arrhythmias. Sotalol was associated with a greater risk of any clinically relevant ventricular arrhythmia as defined by sustained ventricular tachycardia or ICD therapy (hazard ratio [HR] 2.55, 95% CI 1.02–6.39, p=0.045), but this was not statistically significant after adjusting for potential confounders. An increased risk of any ICD shock and first clinically relevant ventricular arrhythmia while on sotalol remained significant after multivariable adjustment. Those on amiodarone (n=10) had a significantly lower risk of any clinically relevant ventricular arrhythmia (HR 0.25, 95% CI 0.07–0.95, p=0.041), a finding that remained significant after multivariable adjustment. In a cohort of well characterized ARVC subjects, neither beta-blockers nor sotalol appeared to be protective. Evidence from a small number of patients suggests that amiodarone has superior efficacy in preventing ventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
Marcus et al. (2009) conducted a cohort in Arrhythmogenic right ventricular cardiomyopathy (ARVC) (n=95). Amiodarone vs. No amiodarone was evaluated on Any clinically relevant ventricular arrhythmia (sustained ventricular tachycardia or ICD therapy) (HR 0.25, 95% CI 0.07-0.95, p=0.041). Amiodarone use in ARVC patients with ICDs was associated with a lower risk of clinically relevant ventricular arrhythmias.
Synapse has enriched 10 related papers. Consider them for comparative context: